Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) reported its second-quarter 2025 financial results on Wednesday, reflecting a mixed performance amid continued shifts in its portfolio strategy.
The company reported total revenue of $4.20 billion, falling short of analysts’ expectations of $4.29 billion, according to Benzinga Pro. This marks a flat year-over-year result in U.S. dollars, with a slight decline of 1% in local currency terms.
